Mohammed Amine Achhal El Kadmiri
Hematology & Oncology · Nashville, TNNPI 1457614778
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 10.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in TN, where the typical reported total is $5,575.
Across 78 payments — averaging $33.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$260
- Johnson & Johnson$214
- Genentech USA, Inc.$207
- E.r. Squibb & Sons, L.L.C.$170
- Regeneron Healthcare Solutions, Inc.$148
- Sanofi$147
- plus $1K from 18 others
Across 5 payments — averaging $11,220 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$28K
- AstraZeneca$27K
- Pharmacyclics LLC, An Abbvie Company$200
What the payments were for
- Food & beverage$2,581100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $260 |
| Johnson & Johnson(2 entities) | 8 | $214 |
| Genentech USA, Inc. | 6 | $207 |
| E.r. Squibb & Sons, L.L.C. | 4 | $170 |
| Regeneron Healthcare Solutions, Inc. | 4 | $148 |
| Sanofi | 3 | $147 |
| Eisai Inc. | 2 | $147 |
| Tempus AI, Inc | 6 | $140 |
| Emmaus Medical, Inc. | 5 | $139 |
| Incyte Corporation | 1 | $128 |
| Teva Pharmaceuticals USA, Inc. | 1 | $126 |
| Novartis | 3 | $124 |
| Daiichi Sankyo Inc. | 4 | $113 |
| Gilead | 4 | $92 |
| Pfizer | 4 | $78 |
| Lilly USA, LLC | 3 | $72 |
| Amgen | 3 | $50 |
| Seagen Inc. | 2 | $47 |
| Bristol Myers Squibb | 2 | $43 |
| Exelixis Inc. | 2 | $35 |
| UCB, Inc. | 1 | $35 |
| AVEO Pharmaceuticals, Inc. | 1 | $27 |
| Acrotech Biopharma Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,593 in reported general payments places this provider in the 30th percentile of 251 hematology & oncology providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 11 | $1,745 |
| Oxycodone Hcl | 41 | $1,321 |
| Anastrozole | 28 | $581 |
| Morphine Sulfate ErMorphine Sulfate | 17 | $489 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Nashville
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
- Olalekan OluwoleNashville$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.